Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Non-Current Debt: 2024-2025

Historic Non-Current Debt for bioAffinity Technologies (BIAF) over the last 2 years, with Sep 2025 value amounting to $43,658.

  • bioAffinity Technologies' Non-Current Debt rose 101.38% to $43,658 in Q3 2025 from the same period last year, while for Sep 2025 it was $43,658, marking a year-over-year increase of 101.38%. This contributed to the annual value of $20,180 for FY2024, which is N/A change from last year.
  • As of Q3 2025, bioAffinity Technologies' Non-Current Debt stood at $43,658, which was down 4.99% from $45,952 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Non-Current Debt high stood at $48,156 for Q1 2025, and its period low was $20,180 during Q4 2024.
  • Over the past 2 years, bioAffinity Technologies' median Non-Current Debt value was $23,037 (recorded in 2024), while the average stood at $32,204.
  • Data for bioAffinity Technologies' Non-Current Debt shows a peak YoY skyrocketed of 109.04% (in 2025) over the last 5 years.
  • Over the past 2 years, bioAffinity Technologies' Non-Current Debt (Quarterly) stood at $20,180 in 2024, then spiked by 101.38% to $43,658 in 2025.
  • Its Non-Current Debt was $43,658 in Q3 2025, compared to $45,952 in Q2 2025 and $48,156 in Q1 2025.